This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...

HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- ...

VOQUEZNA met its primary endpoint in its Phase 3 pivotal trial by demonstrating a significant and rapid reduction of heartburn with daily treatment VOQUEZNA represents the first major innovation in ...

Milsaperidone is an active metabolite of iloperidone ...

Planning for a December 2023 U.S. launch for H. pylori, together with the U.S. launch of vonoprazan for Erosive GERD, if approved Adverse event (AE) rates for the vonoprazan-based regimens were ...

The U.S. Food and Drug Administration has approved milsaperidone (Bysanti) tablets as a first-line therapy for adults with schizophrenia and manic or mixed episodes of bipolar I disorder, ...

Doxycycline is a generic prescription drug used to treat certain types of infections and other conditions. The drug comes as an oral tablet and oral capsule. Doxycycline belongs to a group of drugs ...

Bactrim is prescribed to treat certain infections, such as urinary tract infections or traveler’s diarrhea. Dosages of Bactrim may vary based on the condition being treated. Bactrim is typically taken ...

The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...

This press release is not intended for UK media HERNEXEOS (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as demonstrated in the Beamion LUNG-1 clinical trial1 Acceler ...